Brief: RenovoRx FY Net Income USD -11.168 Million
30/03/2026 21:05
Mar 30 (Reuters) - RenovoRx FY operating expenses USD 13.306 million. FY basic EPS USD -0.32
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies